HFS
NWBO

Hantz Financial Services’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

Hantz Financial Services’s Portfolio NWBO Stock Details NWBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$0 Hold
250
– – ﹤0.01% 2641
2025
Q4 		$0 Hold
250
– – ﹤0.01% 2569
2025
Q3 		$0 Hold
250
– – ﹤0.01% 2480
2025
Q2 		$0 Hold
250
– – ﹤0.01% 2334
2025
Q1 		$0 Hold
250
– – ﹤0.01% 2029
2024
Q4 		$0 Hold
250
– – ﹤0.01% 1249
2024
Q3 		$0 Hold
250
– – ﹤0.01% 1225
2024
Q2 		$0 Hold
250
– – ﹤0.01% 1331
2024
Q1 		$0 Hold
250
– – ﹤0.01% 1332
2023
Q4 		$0 Hold
250
– – ﹤0.01% 1266
2023
Q3 		$0 Hold
250
– – ﹤0.01% 1225
2023
Q2 		$0 Hold
250
– – ﹤0.01% 1219
2023
Q1 		$0 Hold
250
– – ﹤0.01% 1242
2022
Q4 		$0 Hold
250
– – ﹤0.01% 1198
2022
Q3 		$0 Hold
250
– – ﹤0.01% 1171
2022
Q2 		$0 Hold
250
– – ﹤0.01% 1153
2022
Q1 		$0 Buy
+250
New – ﹤0.01% 1154

Other funds holding NWBO

KFA
Kelleher Financial Advisors New York $395M AUM 12.89% 1-Year Est. Return
VWA
VSM Wealth Advisory Hunt Valley, Maryland $335M AUM 16.18% 1-Year Est. Return
OCG
Opus Capital Group Cincinnati, Ohio $930M AUM 16.14% 1-Year Est. Return
EFG
Ethos Financial Group King Of Prussia, Pennsylvania $1.37B AUM 19.43% 1-Year Est. Return
WJWM
Williams Jones Wealth Management New York $8.14B AUM 19.32% 1-Year Est. Return
ME
McIlrath & Eck Arlington, Washington $1.35B AUM 15.78% 1-Year Est. Return

Hantz Financial Services's NWBO Position: Q1 2026 in Review

Hantz Financial Services held its Northwest Biotherapeutics, Inc. Common stock (NWBO) position steady in Q1 2026 at 250 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #2641.

Hantz Financial Services first reported a position in NWBO in Q1 2022 and has held it in 17 quarters since. 8 funds tracked by Wall St. Rank hold NWBO as of Q1 2026.

  • Hantz Financial Services held 250 shares of Northwest Biotherapeutics, Inc. Common stock worth $0 as of Q1 2026.
  • Hantz Financial Services left its Northwest Biotherapeutics, Inc. Common stock share count unchanged in Q1 2026.
  • Northwest Biotherapeutics, Inc. Common stock made up ﹤0.01% of Hantz Financial Services's portfolio in Q1 2026, its #2641 holding.
  • Hantz Financial Services first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q1 2022 and has held it in 17 quarters since.
  • 8 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q1 2026.

Based on Hantz Financial Services's 13F filing for Q1 2026, filed 1 May 2026.